SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Panobacumab

Cat. No.:	HY-P99214
CAS No.:	885053-97-4
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of ***P. aeruginosa***[1].

In Vitro

Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×10^7 $M^{-1}\pm 2.8\times10^7$ M^{-1}[1].

Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis of P. aeruginosa serotype O11 with an IC_{50} of 0.16 ng/mL[1].

Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing of P. aeruginosa serotype O11 cells in a dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1].

Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NMRI mice, murine burn wound model[1]
Dosage:	1, 2, or 4 mg/kg
Administration:	Intravenous injection, single dose
Result:	Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge.

Animal Model:	BALB/c mice, acute lung infection model[1]
Dosage:	0.005 to 0.4 mg/kg
Administration:	Intravenous injection, single dose
Result:	Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P.

	aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection.

REFERENCES

[1]. Horn MP, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010 Jun;54(6):2338-44.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA